1. Home
  2. EFC vs COLL Comparison

EFC vs COLL Comparison

Compare EFC & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EFC
  • COLL
  • Stock Information
  • Founded
  • EFC 2007
  • COLL 2002
  • Country
  • EFC United States
  • COLL United States
  • Employees
  • EFC N/A
  • COLL N/A
  • Industry
  • EFC Real Estate
  • COLL Biotechnology: Pharmaceutical Preparations
  • Sector
  • EFC Finance
  • COLL Health Care
  • Exchange
  • EFC Nasdaq
  • COLL Nasdaq
  • Market Cap
  • EFC 1.1B
  • COLL 1.0B
  • IPO Year
  • EFC 2010
  • COLL 2015
  • Fundamental
  • Price
  • EFC $12.45
  • COLL $31.84
  • Analyst Decision
  • EFC Buy
  • COLL Strong Buy
  • Analyst Count
  • EFC 5
  • COLL 5
  • Target Price
  • EFC $13.69
  • COLL $43.80
  • AVG Volume (30 Days)
  • EFC 809.9K
  • COLL 412.7K
  • Earning Date
  • EFC 02-24-2025
  • COLL 02-20-2025
  • Dividend Yield
  • EFC 12.53%
  • COLL N/A
  • EPS Growth
  • EFC 21.68
  • COLL 757.11
  • EPS
  • EFC 1.32
  • COLL 2.16
  • Revenue
  • EFC $290,293,000.00
  • COLL $599,245,000.00
  • Revenue This Year
  • EFC N/A
  • COLL $13.25
  • Revenue Next Year
  • EFC $26.40
  • COLL $18.14
  • P/E Ratio
  • EFC $9.46
  • COLL $14.72
  • Revenue Growth
  • EFC 12.72
  • COLL 9.62
  • 52 Week Low
  • EFC $10.88
  • COLL $28.39
  • 52 Week High
  • EFC $13.46
  • COLL $42.29
  • Technical
  • Relative Strength Index (RSI)
  • EFC 56.26
  • COLL 51.93
  • Support Level
  • EFC $11.91
  • COLL $32.29
  • Resistance Level
  • EFC $12.63
  • COLL $33.99
  • Average True Range (ATR)
  • EFC 0.16
  • COLL 1.41
  • MACD
  • EFC 0.04
  • COLL 0.19
  • Stochastic Oscillator
  • EFC 74.31
  • COLL 60.79

About EFC Ellington Financial Inc.

Ellington Financial Inc is a specialty finance company. Its primary investment objective is to generate attractive, risk-adjusted total returns for its shareholders by making investments. The company has two reportable segments; The Investment Portfolio Segment is focused on investing in a diverse array of financial assets, including residential and commercial mortgage loans, residential mortgage-backed securities, non-mortgage- and mortgage-related derivatives, debt and equity investments in loan origination companies, and other strategic investments, and The Longbridge Segment is focused on the origination and servicing of reverse mortgage loans. it acquires reverse mortgage loans both through its origination activities and through secondary market purchases.

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Share on Social Networks: